X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs AUROBINDO PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES AUROBINDO PHARMA PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
 
P/E (TTM) x 7.5 19.6 38.1% View Chart
P/BV x 1.3 3.7 36.4% View Chart
Dividend Yield % 1.2 0.3 357.9%  

Financials

 PIRAMAL ENTERPRISES   AUROBINDO PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
AUROBINDO PHARMA
Mar-18
PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,083809 381.1%   
Low Rs1,902504 377.4%   
Sales per share (Unadj.) Rs589.7281.1 209.8%  
Earnings per share (Unadj.) Rs284.041.4 686.8%  
Cash flow per share (Unadj.) Rs310.550.9 610.3%  
Dividends per share (Unadj.) Rs25.002.50 1,000.0%  
Dividend yield (eoy) %1.00.4 263.4%  
Book value per share (Unadj.) Rs1,467.0199.4 735.8%  
Shares outstanding (eoy) m180.27585.88 30.8%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.22.3 180.9%   
Avg P/E ratio x8.815.9 55.3%  
P/CF ratio (eoy) x8.012.9 62.2%  
Price / Book Value ratio x1.73.3 51.6%  
Dividend payout %8.86.0 145.6%   
Avg Mkt Cap Rs m449,332384,630 116.8%   
No. of employees `0006.817.3 39.5%   
Total wages/salary Rs m19,88121,308 93.3%   
Avg. sales/employee Rs Th15,535.69,500.7 163.5%   
Avg. wages/employee Rs Th2,905.41,229.4 236.3%   
Avg. net profit/employee Rs Th7,482.51,397.9 535.3%   
INCOME DATA
Net Sales Rs m106,310164,666 64.6%  
Other income Rs m2,5951,020 254.5%   
Total revenues Rs m108,906165,686 65.7%   
Gross profit Rs m51,59937,718 136.8%  
Depreciation Rs m4,7735,580 85.5%   
Interest Rs m29,783777 3,832.1%   
Profit before tax Rs m19,63832,380 60.6%   
Minority Interest Rs m2,80131 8,920.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,7648,183 -351.5%   
Profit after tax Rs m51,20324,229 211.3%  
Gross profit margin %48.522.9 211.9%  
Effective tax rate %-146.525.3 -579.6%   
Net profit margin %48.214.7 327.3%  
BALANCE SHEET DATA
Current assets Rs m118,154121,878 96.9%   
Current liabilities Rs m462,26086,806 532.5%   
Net working cap to sales %-323.721.3 -1,519.7%  
Current ratio x0.31.4 18.2%  
Inventory Days Days27130 20.5%  
Debtors Days Days4768 68.1%  
Net fixed assets Rs m113,72781,037 140.3%   
Share capital Rs m361586 61.5%   
"Free" reserves Rs m264,093116,218 227.2%   
Net worth Rs m264,454116,804 226.4%   
Long term debt Rs m242,2064,512 5,368.0%   
Total assets Rs m726,834211,052 344.4%  
Interest coverage x1.742.7 3.9%   
Debt to equity ratio x0.90 2,371.0%  
Sales to assets ratio x0.10.8 18.7%   
Return on assets %11.111.8 94.0%  
Return on equity %19.420.7 93.3%  
Return on capital %10.327.4 37.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11080,727 18.7%   
Fx outflow Rs m4,29834,700 12.4%   
Net fx Rs m10,81346,027 23.5%   
CASH FLOW
From Operations Rs m-159,66619,548 -816.8%  
From Investments Rs m-17,677-19,570 90.3%  
From Financial Activity Rs m186,5038,642 2,158.2%  
Net Cashflow Rs m9,3648,922 105.0%  

Share Holding

Indian Promoters % 52.9 54.1 97.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 8.0 50.3%  
FIIs % 26.6 27.7 96.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.2 161.8%  
Shareholders   93,274 69,601 134.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks ahead of Election Results; Realty Stocks Plummet(Closing)

Indian share markets settled around 2% lower today following a sell-off in the global markets and due to uncertainty over the outcome of state assembly elections tomorrow.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Dec 10, 2018 03:35 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS